52North: Venture Capital Funding History
52North
To add a bio or update company history, please click update information.
News from 52North
52North
29 Sept 2026
52North raises £3.2m in funding led by Macmillan Cancer Support to support urgent cancer care diagnostics
52North is a medical technology spin-out from the University of Cambridge developing the Aster biomarker platform and Neutrocheck, a rapid finger-prick blood test. Neutrocheck supports remote triaging of chemotherapy patients at risk of neutropenic sepsis to reduce unnecessary emergency hospital visits.
52North
6 Dec 2024
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
52North
- Health
- Cambridge, United Kingdom
- £8.2m
- 52north.health
- Update Information
More venture news
- 20 Oct 2026
XRlabsXRlabs raises a £6.5m seed round led by Playground Global to embed AI Surgical Intelligence into operating rooms
SeedHealth - 16 Oct 2026
Unravel HealthUnravel Health raises a £2.5m seed round led by Conduit and Wrightwood for daily at-home saliva hormone readings
SeedHealth - 14 Oct 2026
StrideStride raises a £4.6m seed round led by Arāya Ventures to offer diagnostics-driven preventative health memberships
SeedHealth
